Renibus Therapeutics Receives FDA Fast Track Designation for RBT-9 Treatment in COVID-19
June 23, 2020 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, June 23, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it has been granted Fast Track designation by the FDA for...
Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™
February 19, 2019 08:02 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812
October 16, 2017 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, PA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...